Minocycline-induced hyperpigmentation treated with a 755-nm Q-switched alexandrite laser.
BACKGROUND
Cutaneous pigmentation associated with minocycline therapy is an unusual adverse effect for which few successful treatments have been described. The pigment changes may persist for years, despite cessation of therapy, and is often cosmetically disfiguring, causing significant embarrassment and psychological depression in those affected. Few safe and effective treatments have been described in the past; however, recent pigment-specific laser technology has shown promise in the treatment of this condition.


OBJECTIVE
The objective was to describe a series of patients with minocycline-induced hyperpigmentation who were successfully treated with a 755-nm Q-switched alexandrite laser.


METHODS
Six patients with minocycline-induced hyperpigmentation on the face or legs were treated with a Q-switched alexandrite laser on a bimonthly basis until pigmentation was eradicated.


RESULTS
Cutaneous pigmentation resolved completely in all patients in an average of four laser sessions. Side effects were limited to transient purpura and mild desquamation without scarring or dyspigmentation.


CONCLUSIONS
Minocycline-induced cutaneous pigmentation can be effectively cleared without risk of adverse sequelae by Q-switched alexandrite (755-nm) laser irradiation.
Alster
Tina S
TS
Washington Institute of Dermatologic Laser Surgery, Washington, DC 20037, USA. talster@skinlaser.com
Gupta
Samir N
SN
D000328:Adult; D000900:Anti-Bacterial Agents / Q000009:adverse effects*; D001608:Beryllium; D005260:Female; D006801:Humans; D017495:Hyperpigmentation / Q000139:chemically induced* / Q000532:radiotherapy*; D053685:Laser Therapy; D008297:Male; D008875:Middle Aged; D008911:Minocycline / Q000009:adverse effects*
D000900:Anti-Bacterial Agents; C112654:alexandrite; D008911:Minocycline; D001608:Beryllium